Introduction: Human Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) which encodes survivin exhibits multiple biological activities, such as cell proliferation and apoptosis. Survivin is overexpressed in numerous malignant diseases including acute myeloid leukemia (AML). Recent studies have shown that the CRISPR/Cas9 nuclease-mediated gene-editing systems are suitable approach's for editing or knocking out various genes including oncogenes. Methods and materials: We used CRISPR-Cas9 to knockout the BIRC5 in the human leukemic cell line, HL60, and KG1, and these cell lines were transfected with either the Cas9-and three sgRNAs expressing plasmids or negative control (scramble) using Lipofectamine 3000. The efficacy of the transfection was determined by quantitative reverse transcription-polymerase chain (RT-qPCR) and surveyor mutation assays. Cell proliferation and apoptosis were measured by MTT assay and flow cytometry, respectively. Results: We have successfully knocked out the BIRC5 gene in these leukemic cells and observed that the BIRC5-knocked out cells by CRISPR/Cas9 showed a significant decrease (30 folds) of survivin at mRNA levels. Moreover, cell death and apoptosis were significantly induced in BIRC5-CRISPR/Cas9-transfected cells compared to the scramble vector. Conclusion: We demonstrated for the first time that targeting BIRC5 by CRISPR/Cas9 technology is a suitable approach for the induction of apoptosis in leukemic cells. However, further studies targeting this gene in primary leukemic cells are required.
Introduction
Acute myeloid leukemia (AML) is a genetically and clinically heterogeneous disorder defined by undifferentiated malignant clonal myeloid cell proliferation which is more common in older adults. [1] [2] [3] Accumulating evidence indicates that a number of mutations and aberrant expression of many genes are involved in the pathogenesis of AML. 4 Although various therapeutic strategies including chemotherapy and bone marrow stem cells transplantation are now available for the treatment of patients with AML, the rate of mortality is still high in these patients. [5] [6] [7] Therefore, there is an urgent need to precisely dissect fundamental molecular mechanisms regulating leukemia and empower personalized medicine strategy via technologically advanced tools. 8 Accordingly, concurrent targeting multiple components of survival, proliferation, and apoptotic pathways in leukemic cells seems to be suitable approaches for future therapeutic strategies.
Human Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), belongs to the inhibitor of apoptosis (IAP) family, encodes survivin protein as a bifunctional regulator of apoptosis inhibition and cell cycle progression. An increasing number of studies have revealed that survivin preferentially upregulated in leukemia and fetal cells, but it does not exist in normal differentiated adult tissues. [9] [10] [11] [12] Since a strong correlation between the elevated survivin expressions and clinicopathological features of a number of cancers has been reported, many Researchers paid attention to target survivin by employing various kinds of molecular and cellular technologies such as antisense oligonucleotides targeting survivin mRNA, 13 induction of specific cytotoxic T cells and generation of antibody against it; 14 however, most of these preclinical studies were not clinically successful. Through technological breakthroughs in the field of biotechnology and molecular medicine over the recent years, now we have come in the "gene editing era". High-throughput genome engineering tools would break new ground by preventing and/or treating the most devastating genetic disorders. In the last decades or so, targetedspecific nucleases, such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the "clustered regularly interspaced short palindromic repeats" (CRISPR)/"CRISPR-associated genes 9" (Cas9), have extremely been used in genetic modification industry. [15] [16] [17] However, CRISPR/Cas9 has been demonstrated as an easy-handle, highly specific and efficient approach for editing the eukaryotic genome. 18 As survivin plays vital roles in inhibition of apoptosis and cell death in leukemic cells, here we set out to explore the disruption of its gene, BIRC5 by CRISPR/Cas9. Herein, we demonstrated that knockout of BIRC5 by CRISPR/Cas9 in leukemic cells is technically feasible and efficient, also this gene-editing leads to induction of apoptosis and inhibition of cell growth. Moreover, our data show the therapeutic application of CRISPR/Cas9 for disruption of oncogenic BIRC5 in cancers including leukemia.
Materials And Methods

Cell Culture
The human erythroleukemia KG1 cell line and human promyelocytic leukemia HL60 were obtained from Pasteur Institute of Iran. The cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, USA) containing 10% heat-inactivated (30 min, 56°C) fetal bovine serum (FBS) (Gibco, Langley, OK), 1% Glutamax (Gibco), 1% penicillin/streptomycin at 37°C and 5% CO 2 in fully humidified incubator.
Vector Construction And Expression
CRISPR/Cas9 system was purchased from GeneCopoeia (Rockville, MD). To drive the expression of the Cas9 protein, Cas9 nuclease expression clone was specifically designed to have CMV promoter, a mammalian antibiotic resistance gene as a stable selection marker (Neo), and a reporter gene, mCherry fluorescent protein. Also, the negative control (Scramble) vector for pCRISPR-SG01 was constructed as the same as the sgRNA plasmid backbone which did not contain a sgRNA sequence. Three different sgRNAs (sgRNAa, sgRNAb, and sgRNAc) were then designed to construct the CRISPR/Cas9 to target human BIRC5. Briefly, the sequences of sgRNAa, sgRNAb, and sgRNAc are 5ˊCCAGGCAGGGGGCAACGTCG 3ˊ, 5ˊA CTTACATGGGGTCGTCATC 3ˊ, and 5ˊGGGCAGTCT CACCCGCTCCG 3ˊ, respectively, which targeted exon 1 except for sgRNAb that generated an Indel mutation in exon 2 of the gene. These sequences were separately inserted into the sgRNA expression cassettes of pCRISPR-SG01 vector containing the U6 promoter. All of the vectors were introduced by chemical transformation into the competent E.coli DH5α for cloning purposes using a selectable marker of Ampicillin. These strains were cultured on LB agar plates supplemented with 1 mg/mL Ampicillin at 37°C and subsequently in LB broth, liquid culture, containing Ampicillin in the 37°C shaking incubator at 180 rpm/min speed. Then, all of the plasmids were purified with EndoFree Plasmid Maxi Kit (Qiagen, Germantown, MD) according to the manufacturer's protocol. Daejeon, Korea) 48 hours after transfection, and quantification of gDNA was performed by NanoDrop spectrophotometer (WPA Biowave II, Cambridge, UK). The DNA region encompassing the CRISPR target site in BIRC5 was amplified with Pfu high fidelity DNA Polymerase (Vivantis Technologies, Kuala Lumper, Malaysia) using the sense 5ʹ-GACTACA ACTCCCGGCACAC −3ʹ and antisense 5ʹ-AAGGCA TCAGGCATCTTACG −3ʹ primers. PCR was performed under the standard following conditions: 1 cycle initial denaturation of 3 mins at 95°C, followed by 35 cycles of 1 min at 95°C, 1 min at 59°C, and 1 min at 72°C, with a final 10 mins at 72°C for post extension. Amplified PCR products were simply subjected to electrophoresis on 1.5% agarose gel prestained with DNA Green Viewer (Parstous, Iran) at 80 volts for 30-45 mins. The 868 bp fragment was then excised from the gel and purified using the AccuPrep™ Gel Purification Kit (Bioneer, Daejeon, Korea).
Cell Transfection
Surveyor Mutation Detection Assay
BIRC5 oncogene knockout was examined by the SURVEYOR Mutation Detection Kit (Integrated DNA technologies, USA) according to the producer's instructions. Briefly, 400 ng of equal amounts of the test (transfected) and reference (untransfected) purified PCR products were mixed in a microtube for DNA duplex formation. Then, to promote heteroduplex formation, the PCR products heated and cooled slowly on a Bio-Rad C1000 thermocycler as follows: 1: 95°C for 10 mins; 2: 95°C to 85°C ramping at -2.0°C/s; 3: 85°C for 1 min; 4: 85°C to 75°C ramping at -0.3°C/s; 5: 75°C for 1 min; 6: 75°C to 65°C ramping at -0.3°C/s; 7: 65°C for 1 min; 8: 65°C to 55°C ramping at -0.3°C/s; 9: 55°C for 1 min; 10: 55°C to 45°C ramping at -0.3°C/s; 11: 45°C for 1 min; 12: 45°C to 35°C ramping at -0.3°C/s;13: 35°C for 1 min; 14: 35°C to 25°C ramping at -0.3°C/s; 15: 25°C for 1 min. After reannealing, the samples were immediately kept on ice and 1/10 of the total volume of each reaction mixture 1.5 M of MgCl 2 was added. Next, 1 µL of Surveyor Enhancer S and 1 µL of Surveyor Nuclease were added to the products followed by 60 mins incubation at 42°C. Then, stop solution was added in 1/10 volume of each product and digestion products clearly analyzed by 2% agarose gel. The indel percentage was calculated according to the gray value detected using ImageJ software (NIH, Bethesda, MD). The percentage of mutation was measured using the following formulas wherein a is the integrated intensity of the undigested PCR product and b and c are the integrated intensities of each cleavage product:
RNA Extraction And RT-qPCR Assay
Total RNA was extracted from cells using the YTA Total RNA Purification Mini Kit (Yekta Tajhiz, Tehran, Iran) 48 hrs after transfection, according to the supplier's protocol. Complementary DNA (cDNA) was synthesized from 2 µg total RNA as a template by using random hexamer. Reverse transcription was performed using the RevertAid™ First-Strand cDNA Synthesis (Thermo Fisher Scientific, Germany) for 60 mins at 42°C followed by 70 mins at 5°C with RevertAid Reverse Transcriptase. Quantitative Real-Time PCR (RT-qPCR) assay was carried out with Real Q Plus 2X Master Mix Green high ROX™ Kit (Ampliqon, Denmark). PCR amplification was performed to produce an amplicon of 249 bp in 10 μlit final reaction volume with the SYBR Green detection method using the Step one plus Real-Time PCR System (Applied Biosystems, USA). The sequences of the primer sets were used, including BIRC5-F, 5ʹ-CGCATCTCTA CATTCAAG −3ʹ; BIRC5-R, 5ʹ-ATGTTCCTCTCTCGT GAT −3ʹ; GAPDH-F, 5ʹ-AAGCTCATTTCCTGGTAT −3ʹ; GAPDH-R, 5′-5ʹ-CTTCCTCTTGTGCTCTTG −3ʹ. The cycle conditions used for all genes consist of an initial step of 95°C for 15 mins followed by 40 cycles of 95°C for 30 s; 51.6°C for 30 s and 72°C for 30 s with one cycle melt curve stage of 95°C for 30 s; 60°C for 1 min; and finally, 95°C for 15 s. Relative quantification (RQ) of gene expression was calculated using the comparative C t method and the equation 2 −ΔΔCt after normalization the mRNA levels of target gene with an endogenous housekeeping gene, GAPDH.
Cell Viability Assay
Cell viability was analyzed by the MTT (3-(4, 5-methylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide) viability assay as previously reported. 19 In brief, the cells were seeded in 96-well plates in triplicate at a density of 5 × 10 3 cells per well, 48 hrs after transfection of cells with CRISPR/Cas9 vectors. Next, 20 µL of the colorimetric MTT reagent was directly added to the wells with a final concentration of 1 mg/mL. Then, the cells were incubated for 4 h at 37°C, the medium was discarded completely and 100 µL Dimethyl sulfoxide was added and shacked for 10 min. The optical density (OD) was measured at 570 nm using a microplate reader (Stat Fax, Palm City, FL). The absorbance of control cells was considered as 100%. Percent of cell viability was calculated as = 100-(test OD/control OD) x100.
Apoptosis And Necrosis Assay
Forty-eight hours after transfection, cells were harvested and apoptosis was analyzed as previously reported. 20 The 
Statistical Analysis
Arithmetic means and standard deviations were calculated and statistical significance was defined as P≤0.05 using Student's t-test.
Results
The Design And Validation Of sgRNA Targeting BIRC5
In the present study, we first retrieved the sequence of BIRC5 gene (NCBI Reference Sequence (RefSeq): NG_029069.1) and then performed the designation of sgRNAs. We designed three constructs to express sgRNAs of the CRISPR/Cas9 nuclease toolkit. All of these sgRNAs are in principle composed of 20 nt in length, preceded by the canonical trinucleotide 5ˊ-NGG, the protospacer adjacent motif (PAM). The plasmidbased sgRNA expression constructs possess the U6 RNA polymerase III promoter, which, in turn, prefers a guanine (G) nucleotide as the first base of its transcript; thus, an extra G residue is added at the 5′ of the sgRNA. To minimize the off-target mutations, the DNA target site should entirely match the PAM motif as well as the 12 bp seed sequence closest to the PAM; the remaining bases are thought to be less important as their mismatches could be tolerated. In our study, sequences that contained the PAM motif inside exon 1 and/or 2 of BIRC5 were identified. Then, to determine whether or not candidate sequences were unique in the genome, they were analyzed by BLAST (https://blast. ncbi.nlm.nih.gov/Blast.cgi). The schematic features of DNA target sequences and their corresponding sgRNAs are depicted in Figure 1A and B.
Optimizing Cas9/SgRNAs Delivery Of Leukemic Cells
We next aimed at optimizing conditions for the co-transfection of Cas9/sgRNA expression plasmids leukemic cells via lipofectamine. For this purpose, we used reporter plasmids mCherry as a reporter gene in Cas9 and scramble vectors. As shown in Figure 1C , fluorescence micrographs of mCherry-transfected cells indicated that Lipofectamine 3000 is an appropriate reagent for delivering Cas9 or scramble in leukemic cells.
Verification Of The Effect Of sgRNAs Targeting Human BIRC5 Gene
To characterize the functionality of Cas9 nuclease, as well as their respective sgRNAs on BIRC5 gene, we used the SURVEYOR nuclease assay. This method is a mismatch-specific DNA endonuclease for indel mutations identification through the generation of double-strand breaks (DSBs) and subsequent NHEJ DNA repair mechanism. Genomic DNA was isolated from transfected cells and screened for the presence of site-specific gene modification by PCR. As shown in Figure 2 , both of the duplex DNA strands were catalyzed at 3 bp upstream of the PAM. Moreover, our data show that PCR amplicon of 868 bp in BIRC5 gene was broken into several smaller fragments, where sgRNAa, sgRNAb, and sgRNAc were cleaved at their 176 bp, 625 bp, and 269 bp positions, respectively ( Figure 2 ). According to these results, we found that all of sgRNAs successfully triggered site-specific cleavage in the BIRC5 gene locus.
Evaluation Of Survivin Expression At mRNA Levels
To confirm that BIRC5 gene was thoroughly disrupted in these leukemic cells, we next examined the expression of survivin at mRNA level by RT-qPCR. We observed that survivin is highly expressed in these cells confirming the previous reports 14 and disruption of BIRC5 by CRISPR/ Cas9 leads to a significant reduction (30 fold) of survivin in these cells. However, the scramble did not show any significant difference in the expression of survivin in both cell lines (Figure 3 ).
The Effect Of CRISPR/Cas9-Mediated BIRC5 Knockout On Cells Survival And Apoptosis Having shown that CRISPR/Cas9-mediated BIRC5 knockout reduces cell viability, we sought to examine if disruption of BIRC5 by CRISPR/Cas9 could lead to the induction of apoptosis. To do this, the cells were stained with Annexin V and PI, and the apoptosis was detected by flow cytometry. As demonstrated in Figure 5 , CRISPR/ Cas9-mediated BIRC5 knockout shows a remarkable induction of apoptosis in both cell lines. However, scramble plasmid did not induce apoptosis in these leukemic cells.
Discussion
The CRISPR/Cas9 technology has been employed on the genome manipulation, modification, and engineering in microorganisms, plants, animals, and humans for experimentally and therapeutically purposes. In the current study, we successfully disrupted the BIRC5 gene in two human leukemic cells and observed that this genome-editing toolkit is not only feasible and easy to handle but also capable of inducing apoptosis and cell death in these leukemic cells.
Previous studies clarified that BIRC5 gene is overexpressed in numerous malignancies such as leukemia and correlated with tumor progression and drug resistance. 9 The most distinctive function of survivin is cell death regulation. This protein cannot directly interact with caspases; it associates with the X-linked inhibitor of apoptosis (XIAP) and represses the caspase-dependent apoptotic pathway. The emerging body of evidence indicates that survivin acts as anti-apoptotic protein, as well as the promotion of cancer cell invasion and migration, implying that survivin can be considered as a noticeable prognostic and metastatic factor in cancerous cells. 21 Several lines of evidence made it apparent that high BIRC5 expression has been associated with substantially inferior, poor, and adverse clinical outcome in AML. 10, 11, 22, 23 Previous studies have demonstrated that the isoforms (−2B, -Ex3 and −3B, except survivin-2α) of survivin are overexpressed in a human AML-M3 cell line, NB4, as well as bone marrow samples from patients. However, their expression was declined after arsenic trioxide (ATO) treatment as a front-line therapy. 10 In 2017,
Pazhang et al 11 have demonstrated survivin was downregulated in another AML-M3 cell line, HL60 following treatment with embelin and celastrol, two anti-tumor agents, and leads to a considerable response improvement to chemotherapeutic agents. Accordingly, another study has revealed that pretreatment with survivin siRNA could synergistically sensitize leukemic cells U937 cells to anticancer drugs and induced apoptosis in these cells. 9 Thus, survivin is a key player in leukemic cells survival and their resistance to chemo regiments; therefore, we hypothesized that BIRC5 knockout with CRISPR/Cas toolkit would result in the induction of apoptosis and cell death in HL60 and KG1. Herein, for the first time, we employed the CRISPR/Cas9 gene knockout system to disrupt the BIRC5 gene in two human leukemic cells. It is obvious that the transfection of non-adherent cells such as leukemic cells is rather difficult than adherent cell line. However, we co-transfected three DNA plasmids into HL60 and KG1 cell lines by lipofectamine 3000. Thus, this novel non-viral-mediated gene-editing method has many advantages of clinical applications such as low cost and safety. In line with our observations, a recent study employed Cas9:sgRNA gene knockout system to disrupt the PDL-1 gene in human lymphocytes. 24 In accordance with our data and previously published reports, we envision that designing of CRISPR/Cas9 toolkit to disrupt overexpressed genes such as survivin in leukemic cells is a feasible and effective approach. Consistently, we have recently reported that CRISPR/ Cas9 nickase (Cas9n) is an alternative approach for knocking out the leukemic cells. 25 Cas9n is a mutated form of Cas9 which stands in need of two heminuclease domain to create a double-stranded break at the target site. 25 We envisioned that both CRISPR/Cas9 and CRISPRCas9n are feasible approaches to generate genetically modified human cells. However, on-target mutations of CRISPR/Cas9 are nearly twice that of CRISPR/Cas9n in HL60 cell lines, but there are equal in the KG1 cells. On the other hand, designing of sgRNAs for CRISPR/Cas9 is more feasible than CRISPR/Cas9n. Altogether, both systems are appropriate methods for editing or knocking out a gene/oncogene. However, each system might be more suitable for a certain type of cells or cancer. Furthermore, we delineated an inverse correlation between survivin protein levels and apoptosis in leukemic cells. Having knocked out cells with CRISPR constructs, we detected an increasing number of programmed cell death, confirming the survivin invaluable function in cancer development, cell survival, and proliferation. Our data are in close agreement with previous ones which unraveled survivin/BIRC5 mechanistic events was the pivotal and ubiquitous nature of tumor progression and clinical manifestation, consequently emerged as an attractive therapeutic target in cancer treatment. [26] [27] [28] [29] Collectively, this study strengthens the idea that cationic lipid delivered efficiently Cas9: sgRNA into leukemic cells and that CRISPR/cas9 editing gene could be an appropriate method for disrupting the overexpressed gene such as BIRC5 which play an important role in the pathogenesis of cancers including leukemia. Further investigations of employing CRISPR/cas9, particularly in an animal model and preclinical studies, may pave the path for personalized medicine and cell therapy.
